Patent EP0336760A2 successfully refreshed from Google Patents.
EP0336760A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Bone-inducing protein
Assignee: Celtrix Pharmaceuticals Inc
•
Filing: 1989-04-06
•
Granted: —
•
Expires: 2009-04-06
Abstract
Abstract An osteogenically active protein, having the sequence (H₂N)-Ala-Lys-Tyr-Asn-Lys-Ile-Lys-Ser-Arg-Gly-Ile-Lys-Ala-Asn-Thr-Phe-Lys-Lys-Leu-His-Asn-Leu-Ser-Phe-Leu-Tyr-Leu-Asp-His-Asn-Ala-Leu-Glu-Ser-Val-Pro-Leu-Asn-Leu-Pro-Glu-Ser-Leu-Arg-Val-Ile-His-Leu-Gln-Phe-Asn-Asn-Ile-Thr-Ser-Ile-Thr-Asp-Asp-Thr-Phe-Cys-Lys-Ala-Asn-Asp-Thr-Ser-Tyr-Ile-Arg-Asp-Arg-Ile-Glu-Glu-Ile-Arg-Leu-Glu-Gly-Asn-Pro-Val-Ile-Leu-Gly-Lys-His-Pro-Asn-Ser-Phe-Ile-Cys-Leu-Lys-Arg-Leu-Pro-Ile-Gly-Ser-Tyr-Ile-Asp-(COOH), and substantially pure polypeptides that are substantially equivalent and substantially homologous thereto is disclosed. Pharmaceutical compositions containing these polypeptides and methods to use them are also disclosed.
Inventors
- 👤 Hanne Bentz
- 👤 Ranga Nathan
- 👤 David M. Rosen
- 👤 James R. Dasch
- 👤 Saeid M. Seyedin
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-24 08:22
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/32; C; C07; C07K; C07K14/00; A61P; A61P43/00; C07K14/435; C07K14/475; C07K14/51; A61K38/00
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
30 words
A substantially pure polypeptide having osteogenic activity and an internal sequence in the N-terminal portion as follows -Lys-Tyr-Asn-Lys-Ile-Lys-Ser-Arg-Gly-Ile-Lys-Ala-Asn-Thr-Phe-Lys-Lys-Leu-His-Asn-Leu-Ser-Phe-Leu-Tyr-Leu-Asp-His-Asn-Ala-Leu-Glu- and substantially pure polypeptides that are substantially equivalent and substantially homologous thereto.
Claim 2
Dependent Claim
30 words
A substantially pure polypeptide having osteogenic activity and an internal sequence in the N-terminal portion as follows -Lys-Tyr-Asn-Lys-Ile-Lys-Ser-Arg-Gly-Ile-Lys-Ala-Asn-Thr-Phe-Lys-Lys-Leu-His-Asn-Leu-Ser-Phe-Leu-Tyr-Leu-Asp-His-Asn-Ala-Leu-Glu- and substantially pure polypeptides that are substantially equivalent and substantially homologous thereto.
Claim 3
Dependent Claim
28 words
The polypeptide of claim 1 wherein the amino acid immediately preceding the initial Lys of the internal sequence is Ala and defines the amino terminal of the polypeptide.
Claim 4
Dependent Claim
42 words
A polypeptide having an internal sequence in the N-terminal portion of the polypeptide as follows: -Lys-Tyr-Asn-Lys-Ile-Lys-Ser-Arg-Gly-Ile-Lys-Ala-Asn-Thr-Phe-Lys-Lys-Leu-His-Asn-Leu-Ser-Phe-Leu-Tyr-Leu-Asp-His-Asn-Ala-Leu-Glu- wherein said polypeptide is deglycosylated relative to a native osteogenically active polypeptide having said sequence and deglycosylated polypeptides that are substantially equivalent and substantially homologous thereto.
Claim 5
Dependent Claim
42 words
A polypeptide having an internal sequence in the N-terminal portion of the polypeptide as follows: -Lys-Tyr-Asn-Lys-Ile-Lys-Ser-Arg-Gly-Ile-Lys-Ala-Asn-Thr-Phe-Lys-Lys-Leu-His-Asn-Leu-Ser-Phe-Leu-Tyr-Leu-Asp-His-Asn-Ala-Leu-Glu- wherein said polypeptide is deglycosylated relative to a native osteogenically active polypeptide having said sequence and deglycosylated polypeptides that are substantially equivalent and substantially homologous thereto.
Claim 6
Dependent Claim
25 words
A substantially pure osteogenically active polypeptide having the following amino acid sequence: (H₂N)-Ala-Lys-Tyr-Asn-Lys-Ile-Lys-Ser-Arg-Gly-Ile-Lys-Ala-Asn-Thr-Phe-Lys-Lys-Leu-His-Asn-Leu-Ser-Phe-Leu-Tyr-Leu-Asp-His-Asn-Ala-Leu-Glu-Ser-Val-Pro-Leu-Asn-Leu-Pro-Glu-Ser-Leu-Arg-Val-Ile-His-Leu-Gln-Phe-Asn-Asn-Ile-Thr-Ser-Ile-Thr-Asp-Asp-Thr-Phe-Cys-Lys-Ala-Asn-Asp-Thr-Ser-Tyr-Ile-Arg-Asp-Arg-Ile-Glu-Glu-Ile-Arg-Leu-Glu-Gly-Asn-Pro-Val-Ile-Leu-Gly-Lys-His-Pro-Asn-Ser-Phe-Ile-Cys-Leu-Lys-Arg-Leu-Pro-Ile-Gly-Ser-Tyr-Ile-Asp-(COOH), and substantially pure polypeptides that are substantially equivalent and substantially homologous thereto.
Claim 7
Dependent Claim
25 words
A substantially pure osteogenically active polypeptide having the following amino acid sequence: (H₂N)-Ala-Lys-Tyr-Asn-Lys-Ile-Lys-Ser-Arg-Gly-Ile-Lys-Ala-Asn-Thr-Phe-Lys-Lys-Leu-His-Asn-Leu-Ser-Phe-Leu-Tyr-Leu-Asp-His-Asn-Ala-Leu-Glu-Ser-Val-Pro-Leu-Asn-Leu-Pro-Glu-Ser-Leu-Arg-Val-Ile-His-Leu-Gln-Phe-Asn-Asn-Ile-Thr-Ser-Ile-Thr-Asp-Asp-Thr-Phe-Cys-Lys-Ala-Asn-Asp-Thr-Ser-Tyr-Ile-Arg-Asp-Arg-Ile-Glu-Glu-Ile-Arg-Leu-Glu-Gly-Asn-Pro-Val-Ile-Leu-Gly-Lys-His-Pro-Asn-Ser-Phe-Ile-Cys-Leu-Lys-Arg-Leu-Pro-Ile-Gly-Ser-Tyr-Ile-Asp-(COOH), and substantially pure polypeptides that are substantially equivalent and substantially homologous thereto.
Claim 8
Dependent Claim
35 words
A polypeptide having the following amino acid sequence: (H₂N)-Ala-Lys-Tyr-Asn-Lys-Ile-Lys-Ser-Arg-Gly-Ile-Lys-Ala-Asn-Thr-Phe-Lys-Lys-Leu-His-Asn-Leu-Ser-Phe-Leu-Tyr-Leu-Asp-His-Asn-Ala-Leu-Glu-Ser-Val-Pro-Leu-Asn-Leu-Pro-Glu-Ser-Leu-Arg-Val-Ile-His-Leu-Gln-Phe-Asn-Asn-Ile-Thr-Ser-Ile-Thr-Asp-Asp-Thr-Phe-Cys-Lys-Ala-Asn-Asp-Thr-Ser-Tyr-Ile-Arg-Asp-Arg-Ile-Glu-Glu-Ile-Arg-Leu-Glu-Gly-Asn-Pro-Val-Ile-Leu-Gly-Lys-His-Pro-Asn-Ser-Phe-Ile-Cys-Leu-Lys-Arg-Leu-Pro-Ile-Gly-Ser-Tyr-Ile-Asp-(COOH), wherein said polypeptide is deglycosylated relative to a native osteogenically active polypeptide having said sequence and deglycosylated polypeptides that are substantially equivalent and substantially homologous thereto.
Claim 9
Dependent Claim
35 words
A polypeptide having the following amino acid sequence: (H₂N)-Ala-Lys-Tyr-Asn-Lys-Ile-Lys-Ser-Arg-Gly-Ile-Lys-Ala-Asn-Thr-Phe-Lys-Lys-Leu-His-Asn-Leu-Ser-Phe-Leu-Tyr-Leu-Asp-His-Asn-Ala-Leu-Glu-Ser-Val-Pro-Leu-Asn-Leu-Pro-Glu-Ser-Leu-Arg-Val-Ile-His-Leu-Gln-Phe-Asn-Asn-Ile-Thr-Ser-Ile-Thr-Asp-Asp-Thr-Phe-Cys-Lys-Ala-Asn-Asp-Thr-Ser-Tyr-Ile-Arg-Asp-Arg-Ile-Glu-Glu-Ile-Arg-Leu-Glu-Gly-Asn-Pro-Val-Ile-Leu-Gly-Lys-His-Pro-Asn-Ser-Phe-Ile-Cys-Leu-Lys-Arg-Leu-Pro-Ile-Gly-Ser-Tyr-Ile-Asp-(COOH), wherein said polypeptide is deglycosylated relative to a native osteogenically active polypeptide having said sequence and deglycosylated polypeptides that are substantially equivalent and substantially homologous thereto.
Claim 10
Dependent Claim
25 words
A composition for inducing bone formation and/or inhibiting bone resorption comprising an effective amount of an osteogenically active polypeptide of claim 1, 2 or 4.
Claim 11
Dependent Claim
13 words
The composition of claim 6 which further includes an effective amount of TGF-beta.
Claim 12
Dependent Claim
28 words
A method of inducing bone formation in vivo at a predetermined site in a living mammal comprising placing the composition of claim 6 or 7 at said site.
Claim 13
Dependent Claim
29 words
A method of inducing bone marrow cell production in a living mammal comprising administering an effective amount of the composition of claim 6 or 7 to the mammal systemically.
Claim 14
Dependent Claim
26 words
A method of treating osteoporosis in a living mammal comprising administering an effective amount of the composition of claim 6 or 7 to the mammal systemically.
Claim 15
Dependent Claim
52 words
In the method of treating a living mammal for a cancer of the hematopoietic system comprising irradiating the mammal to kill neoplastic hematopoietic cells, the improvement comprising administering a sufficient amount of the composition of claim 6 or 7 to the mammal systemically after said irradiation to stimulate hematopoietic stem cell division.
Claim 16
Dependent Claim
27 words
The method of claim 11 wherein a sufficient amount of TGF-beta is administered systemically to the mammal prior to said irradiation to suppress hematopoietic stem cell division.
Claim 17
Dependent Claim
14 words
Antibody that binds to a polypeptide of claim 1, 2, 3, 4 or 5.
Claim 18
Dependent Claim
14 words
A recombinant polynucleotide encoding a polypeptide of claim 1, 2, 3, 4 or 5.
Claim 19
Dependent Claim
21 words
A recombinant vector containing a recombinant polynucleotide of claim 14 and capable of directing the expression of the polypeptide encoded thereby.
Claim 20
Dependent Claim
21 words
A recombinant host cell or microorganism containing the recombinant vector of claim 15 and capable of permitting expression of said polypeptide.
Claim 21
Dependent Claim
25 words
A process for producing a polypeptide of claim 1, 2, 3, 4 or 5 comprising culturing the recombinant host cell or microorganism of claim 16.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.